Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interleukin-2 × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 110 Other hematologic neoplasm 58 Genitourinary 55 Lymphoid 42 Gastrointestinal 32 Thoracic 28 Breast 28 Gynecologic 27 CNS 21 Other solid neoplasm 18 Head & Neck 17 Myeloid 12 Sarcoma 10 Plasma cell 8 Tumor-Agnostic 6 Classical hematology 2 NET 1 Endocrine 1

Conditions

Sarcoma 1 Neuroendocrine Tumors 1 Head and Neck Neoplasms 1

Interventions

lutetium Lu 177 dotatate 48 Everolimus 40 Magnetic Resonance Spectroscopy 21 lanreotide 17 Temozolomide 17 gallium Ga 68 dotatate 15 Octreotide 15 pembrolizumab 13 Nivolumab 13 surufatinib 12 Capecitabine 12 cabozantinib 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 Sunitinib 10 pasireotide 9 Specimen Handling 9 Positron Emission Tomography Computed Tomography 9 Lutetium-177 9 3-Iodobenzylguanidine 9 Ga(III)-DOTATOC 8 Carboplatin 8 telotristat ethyl 6 copper dotatate CU-64 6 amino-acid, glucose, and electrolyte solution 6 Somatostatin 6 Ipilimumab 6 Fluorodeoxyglucose F18 6 Etoposide 6 Cisplatin 6 90Y-octreotide, DOTA-Tyr(3)- 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04166006 2024-09-19

RaC-Ad

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Recruiting

EndocrineHead & NeckNETSarcoma

Head and Neck Neoplasms, Sarcoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡